BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

670 related articles for article (PubMed ID: 33926418)

  • 21. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
    Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
    Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to First-line Recurrence Treatment Influences Survival in Hormone Receptor-positive, HER2-negative Breast Cancer: A Multicenter Study.
    Yamamura J; Kamigaki S; Tsujie M; Fujita J; Osato H; Higashi C; Kanaizumi H; Tanaka Y; Hamada M; Shinzaki W; Hashimoto Y; Komoike Y
    In Vivo; 2019; 33(1):281-287. PubMed ID: 30587637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different Breast Cancer Subtypes Show Different Metastatic Patterns: A Study from A Large Public Database.
    Guo Y; Arciero CA; Jiang R; Behera M; Peng L; Li X
    Asian Pac J Cancer Prev; 2020 Dec; 21(12):3587-3593. PubMed ID: 33369456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B
    Stueber TN; Wischnewsky M; Leinert E; Diessner J; Bartmann C; Stein RG; Woeckel A
    Clin Breast Cancer; 2019 Oct; 19(5):333-339. PubMed ID: 31281053
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer.
    Klar N; Rosenzweig M; Diergaarde B; Brufsky A
    Clin Breast Cancer; 2019 Aug; 19(4):304-310. PubMed ID: 30827763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen.
    Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE
    J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
    Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Distinct Characteristics and Metastatic Behaviors of Late Recurrence in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Breast Cancer: A Single Institute Experience of More Than 10 Years.
    Chen X; Fan Y; Xu B
    Clin Breast Cancer; 2018 Dec; 18(6):e1353-e1360. PubMed ID: 30201586
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploring prognostic factors for HER2-positive metastatic breast cancer: a retrospective cohort study in a major Swiss hospital.
    Bringolf L; Pestalozzi B; Fink D; Dedes K
    Swiss Med Wkly; 2016; 146():w14393. PubMed ID: 28102883
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Value and Influence of Receptor Conversion on Treatment Regimen in Metastatic Breast Cancer at the First Time of Recurrence.
    Shen J; Xu L; Shi J; Zhao L; Shi S; Feng J; Han X; Shi Y; Wei Q; Wang D; Sun M; Mi X; Teng Y
    Oncol Res Treat; 2020; 43(11):620-627. PubMed ID: 32966998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Surgery of primary tumour has survival benefit in metastatic breast cancer with single-organ metastasis, especially bone.
    Rhu J; Lee SK; Kil WH; Lee JE; Nam SJ
    ANZ J Surg; 2015 Apr; 85(4):240-4. PubMed ID: 25996008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disparities in the survival improvement of recurrent breast cancer.
    Anan K; Mitsuyama S; Koga K; Tanabe R; Saimura M; Tanabe Y; Watanabe M; Suehara N; Matsunaga H; Nishihara K; Abe Y; Nakano T; Tamae K; Ono M; Toyoshima S
    Breast Cancer; 2010; 17(1):48-55. PubMed ID: 19350357
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients.
    Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF
    Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prolonged survival after diagnosis of brain metastasis from breast cancer: contributing factors and treatment implications.
    Honda Y; Aruga T; Yamashita T; Miyamoto H; Horiguchi K; Kitagawa D; Idera N; Goto R; Kuroi K
    Jpn J Clin Oncol; 2015 Aug; 45(8):713-8. PubMed ID: 25981620
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinicopathological and prognostic significance of Ki-67 immunohistochemical expression of distant metastatic lesions in patients with metastatic breast cancer.
    Inari H; Suganuma N; Kawachi K; Yoshida T; Yamanaka T; Nakamura Y; Yoshihara M; Nakayama H; Masudo K; Oshima T; Yokose T; Rino Y; Shimizu S; Miyagi Y; Masuda M
    Breast Cancer; 2017 Nov; 24(6):748-755. PubMed ID: 28425014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic analysis of clinical breast cancer subtypes among patients with liver metastases from breast cancer.
    Duan XF; Dong NN; Zhang T; Li Q
    Int J Clin Oncol; 2013 Feb; 18(1):26-32. PubMed ID: 22041927
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thirty-Year Trends of Survival and Time-Varying Effects of Prognostic Factors in Patients With Metastatic Breast Cancer-A Single Institution Experience.
    Rogoz B; Houzé de l'Aulnoit A; Duhamel A; Houzé de l'Aulnoit D
    Clin Breast Cancer; 2018 Jun; 18(3):246-253. PubMed ID: 28988656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of HER2 status on distant recurrence in early stage breast cancer.
    Hess KR; Esteva FJ
    Breast Cancer Res Treat; 2013 Jan; 137(2):449-55. PubMed ID: 23225147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Endocrine sensitivity is decisive for patient outcome in small node-negative breast cancers (BC) (pT1a,b) - results from the Munich Cancer Registry.
    Kolben T; Harbeck N; Wuerstlein R; Schubert-Fritschle G; Bauerfeind I; Schrodi S; Engel J
    Breast; 2015 Feb; 24(1):24-31. PubMed ID: 25543874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.